VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 538,529 shares, an increase of 101.2% from the July 15th total of 267,687 shares. Approximately 6.7% of the company’s stock are short sold. Based on an average daily volume of 308,439 shares, the short-interest ratio is currently 1.7 days.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on VNRX. Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a report on Thursday, June 18th. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday, April 20th. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. Finally, D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, VolitionRX has an average rating of “Hold” and an average target price of $28.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in VolitionRX in the third quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX in the second quarter valued at $52,000. Geode Capital Management LLC lifted its stake in VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of VolitionRX during the fourth quarter valued at $28,000. Finally, Squarepoint Ops LLC acquired a new position in shares of VolitionRX during the fourth quarter valued at $34,000. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRX Stock Down 14.8%

NYSEAMERICAN:VNRX traded down $0.09 during trading hours on Friday, reaching $0.54. 952,532 shares of the stock were exchanged, compared to its average volume of 939,791. VolitionRX has a 52 week low of $0.53 and a 52 week high of $15.10. The stock has a market capitalization of $4.64 million, a P/E ratio of -0.14 and a beta of 1.16. The firm has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $2.74.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million. As a group, analysts expect that VolitionRX will post -2.36 earnings per share for the current year.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.